Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Jan 26, 2003

Keywords

ClinConnect Summary

OBJECTIVES:

* Determine the efficacy of cisplatin, ifosfamide, and paclitaxel in patients with unresectable or metastatic urothelial cancer (nontransitional cell histologies).

OUTLINE: Patients receive paclitaxel IV over 3 hours and cisplatin IV over 1 hour on day 1 and ifosfamide IV over 1 hour on days 1-3. Filgrastim (G-CSF) is administered subcutaneously daily beginning on day 6 and continuing through day 17 or until blood counts recover. Treatment continues every 3 weeks for a maximum of 6 courses in the absence of stable or progressive disease after completion of course 2 or complete...

Gender

ALL

Eligibility criteria

• DISEASE CHARACTERISTICS:
• • Histologically proven unresectable or metastatic urothelial cancer
• • No transitional cell histologies
• • Bidimensionally measurable disease
• PATIENT CHARACTERISTICS:
• Age:
• • 18 and over
• Performance status:
• • Karnofsky 60-100%
• Hematopoietic:
• • WBC at least 3,500/mm\^3
• • Platelet count greater than 150,000/mm\^3
• Hepatic:
• • Bilirubin less than 2.0 mg/dL
• Renal:
• • Creatinine less than 1.5 mg/dL OR
• • Creatinine clearance greater than 55 mL/min
• Cardiovascular:
• • No New York Heart Association class III or IV heart disease
• Other:
• • No other concurrent malignancy except basal cell skin cancer
• PRIOR CONCURRENT THERAPY:
• • Biologic therapy
• • Not specified
• • Chemotherapy
• • No prior systemic chemotherapy
• • Endocrine therapy
• • Not specified
• • Radiotherapy
• • At least 3 weeks since prior radiotherapy
• • Surgery
• • Not specified

Trial Officials